(Q50587922)

16 March 2018

editorial

0 references

title

Combination therapy of chronic hepatitis C: an important step but not the final goal! (English)

1 reference

16 March 2018

1 reference

Wedemeyer H

1

1 reference

16 March 2018

Caselmann WH

series ordinal

2

1 reference

16 March 2018

Manns MP

series ordinal

3

1 reference

16 March 2018

publication date

1 December 1998

1 reference

16 March 2018

published in

Journal of Hepatology

1 reference

16 March 2018

volume

29

1 reference

16 March 2018

issue

6

1 reference

16 March 2018

page(s)

1010-1014

1 reference

16 March 2018

The treatment of chronic viral hepatitis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Therapy of hepatitis C: overview

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Reduced long-term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Molecular mechanisms of action of ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Inhibition of immune functions by antiviral drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Effect of ribavirin on viral hepatitis in laboratory animals

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Ribavirin antagonizes the effect of azidothymidine on HIV replication

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Hepatitis B virus immunopathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Type 2 cytokines and negative immune regulation in human infections

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

T-lymphocyte response to hepatitis C virus in different clinical courses of infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Th1-Th2: reliable paradigm or dangerous dogma?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Effects of ribavirin on intrahepatic and extrahepatic expression of hepatitis C virus in interferon nonresponsive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

A pilot study of ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Ribavirin treatment for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Prolonged therapy of chronic hepatitis C with ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Long term follow-up of children hospitalized with respiratory syncytial virus lower respiratory tract infection and randomly treated with ribavirin or placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Long-term outcome of hepatitis C virus infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Graft loss following liver transplantation in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Long-term outcome of hepatitis C infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Histological and clinical outcome after liver transplantation for hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Interferon-alpha therapy for hepatitis C virus infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Synthetic antisense oligodeoxynucleotides as potential drugs against hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

Core specific antisense phosphorothioate oligodeoxynucleotides as potent and specific inhibitors of hepatitis C viral translation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2898%2980133-5

7 January 2021

10.1016/S0168-8278(98)80133-5

Identifiers

DOI

1 reference

16 March 2018

1 reference

16 March 2018